BLOOMBERG: How Long Can Allergan Keep Valeant’s Bid at Bay?

  

Bloomberg’s Drew Armstrong examines Allergan’s rejection of Valeant’s unsolicited offer and actions by the drug maker to find a different buyer other than Valeant. He speaks on Bloomberg Television’s “Market Makers.”